化学免疫疗法
癌症研究
肿瘤微环境
结缔组织增生
纳米凝胶
医学
免疫疗法
免疫学
癌症
免疫系统
药物输送
内科学
胰腺癌
材料科学
肿瘤细胞
纳米技术
作者
Hsuan‐Yu Mu,Yen‐Nhi Ngoc Ta,Max Jing Rui Tham,Fu‐Fei Hsu,Yu‐Chieh Lin,Hsi‐Chien Huang,Yun‐Chieh Sung,Chun Kai Huang,Cheng-Jang Wu,Cheng-Ho Chang,Shuyuan Yang,Tsung‐Ying Lee,Dehui Wan,Jane Wang,Dan G. Duda,Yves Boucher,Jen‐Huang Huang,Wee Han Ang,Yunching Chen
标识
DOI:10.1002/adfm.202303033
摘要
Abstract Interleukin‐2 (IL‐2) is one of the first FDA‐approved immunotherapeutics, but its use is limited by toxicity and low efficacy. In addition, all immunotherapies are limited by the immunosuppressive and desmoplastic microenvironment of “immunologically cold” tumors, such as pancreatic ductal adenocarcinoma (PDAC) or hepatocellular carcinoma (HCC) with advanced liver fibrosis. Here, a new chemoimmunotherapy nanogel (IL2‐Pt@Nanogel) for dual delivery of IL‐2 and the type II immunogenic cell death inducer Pt‐NHC that reduces the immunosuppressive phenotype of tumor‐associated macrophages and diminishes regulatory T cell infiltration by inducing the production of type I interferon (IFN) by cancer cells is reported. Combining the angiotensin II receptor blocker losartan with IL2‐Pt@Nanogel treatment reduces desmoplasia and reprogrammes the microenvironment of PDAC and HCC toward an immunostimulatory one. These effects result in potent anti‐tumor efficacy in models of primary and metastatic PDAC and HCC with underlying liver fibrosis. This study presents a strategy for IL‐2‐based chemoimmunotherapy with the potential for clinical translation to treat solid tumors.
科研通智能强力驱动
Strongly Powered by AbleSci AI